Forum ODDO BHF

January 9-10, 2020 – Lyon, France
Investors conference

ipna-2019-venice-1

J.P. MORGAN

January 13-16, 2020 – San Francisco, CA, USA
Investors conference

ipna-2019-venice-1

SFNP

January 15-17, 2020 – Toulouse, France
Scientific congress

ipna-2019-venice-1
Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

10 + 1 =

© 2019 Advicenne